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Abstract
Background: HIV-1 clade C (HIV-C) predominates worldwide, and anti-HIV-C vaccines are urgently needed. Neutralizing
antibody (nAb) responses are considered important but have proved difficult to elicit. Although some current immunogens
elicit antibodies that neutralize highly neutralization-sensitive (tier 1) HIV strains, most circulating HIVs exhibiting a less
sensitive (tier 2) phenotype are not neutralized. Thus, both tier 1 and 2 viruses are needed for vaccine discovery in
nonhuman primate models.
Methodology/Principal Findings: We constructed a tier 1 simian-human immunodeficiency virus, SHIV-1157ipEL, by inserting an
‘‘early,’’ recently transmitted HIV-C env into the SHIV-1157ipd3N4 backbone [1] encoding a ‘‘late’’ form of the same env, which had
evolved in a SHIV-infected rhesus monkey (RM) with AIDS. SHIV-1157ipEL was rapidly passaged to yield SHIV-1157ipEL-p, which
remained exclusively R5-tropic and had a tier 1 phenotype, in contrast to ‘‘late’’ SHIV-1157ipd3N4 (tier 2). After 5 weekly low-dose
intrarectal exposures, SHIV-1157ipEL-p systemically infected 16 out of 17 RM with high peak viral RNA loads and depleted gut CD4
+
T cells. SHIV-1157ipEL-p and SHIV-1157ipd3N4 env genes diverge mostly in V1/V2. Molecular modeling revealed a possible
mechanism for the increased neutralization resistance of SHIV-1157ipd3N4 Env: V2 loops hindering access to the CD4 binding site,
shown experimentally with nAb b12. Similar mutations have been linked to decreased neutralization sensitivity in HIV-C strains
isolated from humans over time, indicating parallel HIV-C Env evolution in humans and RM.
Conclusions/Significance: SHIV-1157ipEL-p, the first tier 1 R5 clade C SHIV, and SHIV-1157ipd3N4, its tier 2 counterpart,
represent biologically relevant tools for anti-HIV-C vaccine development in primates.
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Introduction
Recent developments in AIDS vaccine research focused
attention on the need for developing vaccine strategies that can
generate both cellular and humoral immunity [2]. Currently, T-
cell as well as nAb-based responses are believed to be necessary for
eliciting an effective response against HIV-1 (reviewed in [3]).
During the course of natural HIV-1 infection, nAbs are generated
that may delay disease progression (reviewed in [4]).
More than 90% of all HIV-1 transmissions occur mucosally,
and almost all of these infections are initiated by R5 strains – even
when the source persons have mixed infections [5]. Therefore,
preclinical primate model studies should focus on vaccine
prevention of mucosal R5 virus transmission. The availability of
a primate model that reflects the salient biologic features of HIV-1
transmission among humans will enhance our understanding of
lentiviral pathogenesis and facilitate the development of an
effective vaccine.
HIV-1 clade C (HIV-C) is the predominant subtype and is
found in .56% of all HIV-1/AIDS cases worldwide (www.unaids.
org). It is associated with the rapidly growing epidemics in
populous regions, such as sub-Saharan Africa, India, and China,
PLoS ONE | www.plosone.org 1 July 2010 | Volume 5 | Issue 7 | e11689where B’/C recombinants with HIV-C env circulate. The
epidemiological data imply an urgent need for vaccines to slow
HIV-C spread.
Several reports have focused on the nature of recently
transmitted HIV-C; these studies involved HIV-1 discordant
heterosexual couples in Zambia that were followed prospectively
[6,7]. Viruses from newly infected individuals were more sensitive
to neutralization by plasma of their chronically infected partners
than contemporaneous viruses isolated from the latter. The newly
transmitted HIV-C strains contained shorter variable loops
compared to HIV-C sequences in the database [6,7]. However,
newly transmitted HIV-C strains overall mostly resemble typical
primary HIV-C isolates with tier 2 neutralization phenotypes,
which was also the case in a recent report by Seaman et al. [8],
where 9 out of 11 relatively recently transmitted HIV-C isolates
(Fiebig # IV; [9]) were classified as tier 2 strains, 2 out of 11 as tier
1 and none as neutralization-resistant tier 3 strains. All of these 11
relatively recently transmitted HIV-C strains were linked to
heterosexual transmission. Together, the data imply that hetero-
sexual mucosal HIV-C transmission events involve viral strains
with envelopes that exhibit at least some level of neutralization
sensitivity in order to establish chronic infection in the new human
host. Therefore, the availability of primate R5 SHIV challenge
viruses that encode tier 1 as well as tier 2 primary HIV-1 envelopes
will be useful for efficacy testing of candidate AIDS vaccines in
macaque models.
There is general agreement that an AIDS vaccine should induce
cellular as well as neutralizing antibody (nAb) responses, but
inducing the latter at sufficiently high titers and breadth to
neutralize typical primary HIV isolates has proven to be a daunting
task. We suggest that development of vaccines designed to induce
anti-HIV nAbs should proceed in a stepwise approach: preclinical
vaccine efficacy studies in primates should first attempt to induce
protection against simian-human immunodeficiency viruses
(SHIVs) encoding primary HIV envelopes that are relatively easy
to neutralize (tier 1 strains). Once this goal has been achieved,
immunogens should then be optimized to induce protection against
the more difficult-to-neutralize tier 2 viruses that exhibit neutral-
ization sensitivity profiles of typical primary HIV isolates.
We have previously generated R5 clade C SHIV (SHIV-C)
strains [1,10,11]. To construct the parental infectious molecular
clone SHIV-1157i, env from the 6-month-old Zambian infant 1157i
born to an HIV-C-positive motherwasinserted into the SHIV-vpu
+
backbone. During prospective long-term follow-up, the Zambian
infant 1157i turned out to be a long-term non-progressor (LTNP)
who has remained asymptomatic [12]. The rhesus monkey (RM)-
adapted strain, SHIV-1157ip, is pathogenic and has caused AIDS
in several monkeys thus far [10], but the rate of disease progression
is relatively slow. The ‘‘early’’ SHIV-1157ip isolate, which had been
adapted to RM through rapid serial passage, was significantly more
sensitive neutralization in an earlier study [13] when compared to
SHIV-1157ipd3N4 [1] the ‘‘late’’ virus version. The latter is an
infectious molecular clone generated by directly cloning the 39 half
of the provirus from peripheral blood mononuclear cells (PBMC) of
the first RM after it had progressed to AIDS. We also engineered
the 39 long terminal repeat of SHIV-1157ipd3N4 to contain an
extra NF-kB site to accelerate viral replication in response to host
cytokines, especially tumor necrosis factor (TNF)-a [1]. This ‘‘late’’
virus is still exclusively R5 tropic; it has a tier 2 neutralization
phenotype [10,11].
Here we report the construction of a tier 1 R5 SHIV, termed
SHIV-1157ipEL, which is a chimera of the ‘‘early’’, neutraliza-
tion-sensitive SHIV-1157ip envelope and the ‘‘late’’, engineered
backbone of SHIV-1157ipd3N4 [1]. The latter is clearly a
neutralization escape variant that evolved in the first RM recipient
of the parental infectious molecular clone. SHIV-1157ipEL was
rapidly passaged through four Indian RM. The passaged virus,
SHIV-1157ipEL-p, was re-isolated from the last recipient within
two weeks of inoculation and characterized. This new virus, a
biological isolate, is exclusively R5-tropic, mucosally transmissible,
and causes T-cell depletion in different anatomical compartments
during acute infection. Furthermore, SHIV-1157ipEL-p is highly
sensitive to neutralization in contrast to the late virus, SHIV-
1157ipd3N4. Molecular modeling of the early and late Env-C
proteins suggests that the orientation of the V2 loops may account
for the differential susceptibility of the early and late Env forms to
neutralization.
Results
The ‘‘late’’ SHIV-1157ipd3N4 is an escape variant
The ‘‘late’’ SHIV-1157ipd3N4 was isolated from monkey RPn-
8 shortly after this animal developed AIDS (ca. 2.7 years post-
inoculation). We compared the ability of autologous plasma
samples collected from this host animal at various time points to
neutralize SHIV-1157ip (early virus) and SHIV-1157ipd3N4 (late
virus) using the TZM-bl cell assay [7,14,15] (Methods). Although
the ‘‘early’’ SHIV-1157ip was effectively neutralized by all plasma
samples of RPn-8 from weeks 89 to 181 (Fig. 1), this RM had
persistently high levels of viremia throughout its course of disease
progression. In contrast, ‘‘late’’ virus was not neutralized by early
and contemporaneous plasma samples; only plasma from the latest
time point (week 181) showed low-level neutralization. These
autologous neutralization data suggest that the ‘‘late’’ SHIV-
1157ipd3N4 arose as a neutralization escape variant in host RPn-8
by selective pressure exerted by high-level nAbs.
Construction of a SHIV-1157ipEL encoding env from an
African infant
The ‘‘late’’ infectious molecular clone, SHIV-1157ipd3N4,
replicates to high levels and is transmissible across all mucosal
surfaces tested [16]. However, it is relatively difficult to neutralize
by active vaccination, e.g., using trimeric gp160 [13]. We sought
to generate a neutralization-sensitive R5 SHIV-C version with the
same optimized backbone present in SHIV-1157ipd3N4 (Table 1).
SHIV-1157ip [10], an early biological isolate obtained after rapid
passage through five RM, was used as source for an ‘‘early’’ HIV-
C env. Full-length env genes were PCR-amplified from DNA
isolated from co-cultured PBMC of a SHIV-1157ip-infected RM
and were cloned into the expression vector pcDNA6/B. SHIV-
1157ipEL was constructed using the late stage virus, SHIV-
1157ipd3N4 [1], as the backbone (Fig. 2A). After exchanging env,
the resulting chimera, SHIV-1157ipEL, contained most of gp120,
the entire extracellular domain, the transmembrane region, and
part of the cytoplasmic tail of gp41 of the early env gene. The initial
cell-free SHIV-1157ipEL clone stock was generated by transfect-
ing 293T cells with infectious proviral DNA and harvesting
supernatant. The stock was tested for infectivity in TZM-bl cells
[7,14,15], which express luciferase and b-galactosidase under the
control of HIV-1 LTR (data not shown). The various R5 SHIV-C
strains and their derivations are summarized in Table 1.
Next, we assessed co-receptor usage of SHIV-1157ipEL with
late stage virus SHIV-1157ipd3N4 and clade B NL4-3 virus as
controls. SHIV-1157ipEL did not replicate in any cell line that
lacked CCR5 (Fig. 2B; Methods). Productive infection was
observed only in U87.CD4.CCR5 cells (Fig. 2B), suggesting that
SHIV-1157ipEL uses CCR5 as an exclusive co-receptor for entry.
R5 HIV Clade C Env Evolution
PLoS ONE | www.plosone.org 2 July 2010 | Volume 5 | Issue 7 | e11689Figure 1. Selection of a neutralization escape variant in rhesus monkey RPn-8. This monkey was inoculated initially with an ‘‘early’’ form of
the virus (the parental infectious molecular clone, SHIV-1157i; see Table 1), and 4 weeks after RPn-8 had progressed to AIDS (,2.7 years), the ‘‘late’’
virus, SHIV-1157ipd3N4 [1], was generated by molecular cloning of the 39 proviral half from RPn-8 PBMC DNA. Neutralization of SHIV-1157ip (‘‘early’’
strain, open triangles) and SHIV-1157ipd3N4 (‘‘late’’ strain, closed circles) with autologous plasma from animal RPn-8 at the time points post-
inoculation indicated is shown (A–D), including contemporaneous plasma for the ‘‘late’’ virus collected at week 139 (panel C). Virus (grown in RM
PBMC) was incubated with different dilutions of monkey plasma for 1 h before being added to TZM-bl cells in the presence of DEAE-dextran.
Luciferase expression was measured on day 2 post-infection.
doi:10.1371/journal.pone.0011689.g001
Table 1. Summary of R5 SHIV-C strains encoding an HIV1157i-related envelope.
Strain Nature of strain
# NF-kB
ites/LTR Derivation
Neutralization
sensitivity Reference
SHIV-1157i parental infectious molecular
clone; not yet adapted to
rhesus monkeys
1 result of initial molecular cloning, given to
recipient monkey RPn-8, which developed AIDS
[1,10]
SHIV-1157ip passaged biological isolate;
pathogenic
1 early virus isolated from monkey Kl-8 (passage 4) tier 1 [10]
SHIV-1157ipd3N4 infectious molecular clone;
pathogenic
2 late-stage virus generated by cloning the 39 proviral
half from infected PBMC of monkey RPn-8 4 weeks
after the onset of AIDS (week 127 post-inoculation).
RPn-8 had received the parental, non-passaged clone,
SHIV-1157i.
tier 2 [1]
SHIV-1157ipEL infectious molecular clone 2 ‘‘early-late’’ chimera generated by swapping env
in the late SHIV-1157ipd3N4 with ‘‘early’’ env;
non-passaged clone
tier 1
SHIV-1157ipEL-p biological isolate 2 passaged chimera reisolated from monkey
ROm-8 (passage 3) at week 2 post-inoculation
tier 1
doi:10.1371/journal.pone.0011689.t001
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Our aim was to create a virus that would replicate reliably in all
unselected, randomly chosen animals of the test species, rhesus
macaques. Since it is well established that the ability of a primate
lentivirus to replicate in cultured PBMC is predictive of its ability
to productively infect the donor monkey, we randomly selected
nine RM as PBMC donors to evaluate the replication kinetics of
parental SHIV-1157ipEL in vitro. Undiluted virus, generated by
transfection of 293T cells with the infectious molecular clone and
followed by collection of cell-free supernatants, was used for the
screen. While the new chimera replicated vigorously in the PBMC
of two of the donors, PBMC of donor monkey RFn-9 did not
support viral replication (Fig. 3A); PBMC cultures of other donors
also yielded only little virus. Clearly, parental SHIV-1157EL was
not replication competent in all PBMC cultures from randomly
selected donor monkeys. This indicated a need to proceed with the
in vivo adaption and the selection of progeny virus with better
replication kinetics.
Adaptation of SHIV-1157ipEL to RM and generation of
SHIV-1157ipEL-p
SHIV-1157ipEL was passaged through four RM (Fig. 4A). To
avoid selection of a neutralization escape virus, we used rapid
animal-to-animal passage of whole blood at the time of peak
viremia (week 2 post-inoculation) to adapt the new SHIV strain
to RM [10,11]. The first macaque, REk-11, was inoculated
intravenously (i.v.) with 10 ml of SHIV-1157ipEL stock (prepared
in RM PBMC that were exposed to the cell-free supernatant of
293T cells transfected with proviral DNA); peak viremia reached
5.2610
7 RNA copies/ml at week 2 post-inoculation (Fig. 4B).
Three additional animals were subjected to serial blood transfer
(Fig. 4A). Passaged virus reached high peak viremia levels in all
recipients, all of which seroconverted (data not shown). We
reisolated virus at week 2 post-inoculation from the final
recipient, ROm-8. The resulting passaged virus, SHIV-
1157ipEL-p, an uncloned biological isolate, was expanded in
RM PBMC.
Figure 2. Construction and co-receptor usage of SHIV-1157ipEL. A. SHIV-1157ipd3N4 [1] was used as backbone to construct SHIV-1157ipEL.
The 2.2 kb KpnI (K) - BamHI (B) fragment of the ‘‘early’’ SHIV-1157ip (spanning most of gp120, the entire gp41 extracellular domain, the
transmembrane region (TM), and part of the cytoplasmic domain) (closed black bar) was used to replace the corresponding region of the proviral
backbone (stippled bar). The modified 39-half of was ligated with the 59 half of SHIV-1157ipd3N4 DNA to form full-length SHIV-1157ipEL. NN: 2 NF-kB
sites present in the 39LTR. During viral replication, this duplication of NF-kB sites copied into the 59LTR. B. Coreceptor usage of SHIV-1157ipEL and
SHIV-1157ipEL-p. U87.CD4.CCR5 and U87.CD4.CXCR4 cells were exposed to parental SHIV-1157ipEL, passaged SHIV-1157ipEL-p, SHIV-1157ipd3N4
(clade C, R5 SHIV), and HIVNL4-3(HIV clade B env, X4). The levels of p27 Gag were measured in the supernatants as indicated.
doi:10.1371/journal.pone.0011689.g002
R5 HIV Clade C Env Evolution
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receptor usage
Next, we assessed co-receptor usage by SHIV-1157ipEL-p.
Productive infection was only seen with the CCR5-expressing cell
line (Fig. 2B), suggesting that SHIV-1157ipEL-p maintained its
exclusive R5 tropism after rapid animal-to-animal passage. We
also tested whether SHIV-1157ipEL-p could grow in the PBMC of
the RM that had previously failed to support the replication of
non-adapted virus as well as in PBMC of other randomly selected
donors. Adapted SHIV-1157ipEL-p replicated vigorously in all
PBMC cultures tested, including PBMC from donor RFn-9 that
had not supported the growth of the parental infectious molecular
clone, SHIV-1157EL (Fig. 3A,B, boxed name), indicating its
successful adaptation to RM.
Phylogenetic analysis
Primary full-length env genes were PCR amplified from genomic
DNA isolated two week post-inoculation from the last recipient
(ROm-8) and cloned into the expression vector pcDNA6/B. As
described previously [11], the env genes of the newly created SHIV
strains clustered with HIV-C in a phylogenetic tree. Among the
strains tested, the closest relationship was found with another set of
SHIV-Cs that was derived from a pediatric HIV-C strain isolated
from an infant belonging to the cohort of HIV-infected mothers/
infants that are being followed prospectively at the University
Hospital in Lusaka, Zambia.
Evolution of SHIV-1157ipEL-p Env during adaptation
Sequence analysis was performed on the SHIV-1157ipEL-p
env gene, which was cloned from genomic DNA of PBMC from
ROm-8, the last RM recipient during the adaption process. Env
DNA amplified from PBMC of ROm-8 (2 weeks after blood
transfer) showed only three point mutations throughout gp160
relative to the parental (SHIV-1157ipEL) Env sequence (data not
shown). This included loss of N295, a key amino acid residue in
the epitope of the broadly reactive neutralizing antibody 2G12.
Not surprisingly, the loss of N295 caused SHIV-1157ipEL to
become resistant to 2G12 (data not shown). The absence of the
2G12 epitope in many primary HIV-C isolates is well known [7].
Neutralization tier profiles
Primary HIV or SHIV strains are classified as tier 1 or tier 2
depending on their sensitivity to neutralization [17]. Tier 1 strains
are markedly neutralization-sensitive; tier 2 strains are more
difficult to neutralize and represent the average neutralization
sensitivity of primary HIV isolates including most recently
transmitted strains of HIV-C [7]. SHIV-1157ipEL and the
passaged virus, SHIV-1157ipEL-p, were tested by TZM-bl assay
against a panel of human neutralizing monoclonal antibodies
(nmAbs) and polyclonal sera collected from HIV-positive individ-
uals. Table 2 shows that the parental molecular clone, SHIV-
1157ipEL, and the passaged biological isolate, SHIV-1157ipEL-p,
Figure 3. Replication of SHIV-1157ipEL and SHIV-1157ipEL-p in
rhesus macaque PBMC. (A) PBMC from randomly selected naı ¨ve RM
donors were stimulated with concanavalin A (Con-A) and exposed to
SHIV-1157ipEL-containing supernatant (Methods). The PBMC of RM
RFn-9 (thick red line) did not support the replication of parental SHIV-
1157ipEL. (B) PBMC from random donors were stimulated with Con-A
and exposed to passaged virus, SHIV-1157ipEL-p. Supernatants were
harvested and p27 levels were measured at the time points indicated.
PBMC cultures of RFn-9 (previously unable to support the replication of
parental virus, see under A) now yielded high levels of p27 (thick red
line), indicating SHIV-1157ipEL-p adaptation to RM. For RM listed in
both A and B, aliquots of frozen PBMC from the same blood collection
as in A were used for assays in B.
doi:10.1371/journal.pone.0011689.g003
Figure 4. Serial passage of SHIV-1157ipEL in rhesus macaques.
(A) Parental SHIV-1157ipEL was passaged rapidly in four Indian-origin
RM through serial blood transfer at peak viremia (week 2). (B) Viral loads
were measured after serial passage at the time points indicated. {, these
RM were euthanized at peak viremia.
doi:10.1371/journal.pone.0011689.g004
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SHIV-1157ipd3N4, is categorized as tier 2 [1]. The fact that the
neutralization profiles of SHIV-1157ipEL and SHIV-1157ipEL-p
are similar indicates that our rapid adaptation strategy, whereby
infected blood was transfused into a new recipient every two
weeks, successfully avoided the outgrowth of a neutralization
escape variant. Another R5 clade C SHIV, SHIV-2873Nip [11],
was also classified as tier 2 strain. SHIVSF162P3 and SHIVSF162P4,
previously classified as tier 2 and tier 1 viruses, respectively, were
used as reference strains in the assay.
SHIV-1157ipEL-p is efficiently neutralized by autologous
and heterologous RM plasma/sera
For a challenge virus to be useful for anti-HIV-C vaccine
development, it should maintain a neutralization-sensitive Env
structure. We assessed SHIV-1157ipEL-p neutralization sensitivity
in TZM-bl cell-based assays with autologous and heterologous
RM plasma or serum samples collected from R5 SHIV-infected
RM throughout the course of infection. As shown in Table 3, all
animals tested developed high nAb titers against SHIV-1157ipEL-
p but only weak or low titers against SHIV-1157ipd3N4. While
these data are consistent with the high susceptibility of the ‘‘early’’
virus, SHIV-1157ipEL-p, to neutralization and compatible with its
tier 1 phenotype, it is interesting to note that even sera from RM
that were chronically infected with the ‘‘late’’ SHIV-1157ipd3N4
developed higher nAb titers against SHIV-1157ipEL-p than
against SHIV-1157ipd3N4 itself. Importantly, sera from RM
infected with the heterologous tier 2 SHIV-2873Nip also
developed strong nAb titers against SHIV-1157ipEL-p and very
low titers against SHIV-1157ipd3N4.
Sequence and structural analysis of SHIV-1157ipEL-p,
SHIV-1157ipEL-pD3N and SHIV-1157ipd3N4
As SHIV-1157ipEL-p and SHIV-1157ipd3N4 share 90%
sequence homology in Env but have different neutralization
profiles, we sought to link structural features with differential
neutralization sensitivity. First, we searched for potential N-linked
glycosylation (PNG) sites present in both SHIV strains. Compared
to SHIV-1157ipd3N4 (containing 25 PNG sites in gp120), SHIV-
1157ipEL-p has an additional PNG site in the V2 loop; all other
PNG sites are identical (Fig. 5A). This PNG site is adjacent to
another one, and steric hindrance might prevent carbohydrate
addition to both asparagines. Of note, many of the tier 1 HIV
sequences contain contiguous PNG sites in the V2 loop [18].
Furthermore, we identified differences in the hypervariable regions
of the two SHIVs. For instance, the V2 loop of SHIV-1157ipEL-p
is longer than that of SHIV-1157ipd3N4 by three amino acids,
namely three asparagines (NNN) at positions 185–187. Also, the
V2 loop N170Y mutation of SHIV-1157ipd3N4 could be
important for access to the CD4 binding site (CD4bs). Interest-
ingly, SHIV-1157ipEL-p has one more basic amino acid in each of
the V1, V2, and V3 loops than SHIV-157ipd3N4 (Fig. 5A), which
may result in increased antibody binding to these loops [19].
Using the established core structure of HIV-1 YU2 Env [20],
we performed molecular modeling to superimpose the gp120
sequences of SHIV-1157ipEL-p, and SHIV-1157ipd3N4 (Fig. 5B).
The main differences between the sequences are located in the V2
loops, which are packed closer to the core of gp120 and the CD4
binding site in SHIV-1157ipd3N4, than in SHIV-1157ipEL-p
(Fig. 5C). Interestingly, the shorter V2 loop of the ‘‘late’’ virus
(Fig. 5C, shown in green) appears to occlude access to the CD4bs
(shown in red), which would make it difficult for anti-CD4bs
nmAbs to bind to their cognate epitopes. Furthermore, molecular
modeling predicted that deletion of the NNN residues at positions
185–187 in the tier 1 SHIV-1157ipEL-p would tilt the V2 loop
toward the CD4bs in a direction analogous to that of the tier 2
SHIV-1157ipd3N4 (Fig. 5D, yellow and green structures) and thus
would likely obstruct access to the CD4bs.
To test this notion, we used site-directed mutagenesis to
construct the NNN-deletion mutant, termed SHIV-1157ipEL-
pD3N (Fig. 5A & D). Next, we tested the neutralization of SHIV-
1157ipEL-p, SHIV-1157ipEL-pD3N and SHIV-1157ipd3N4 by
sCD4 and b12 in the TZM-bl assay (Fig. 6A). All three viruses
exhibited similar neutralization sensitivity to soluble CD4 (sCD4).
However, a major difference was observed for b12. Indeed, while
this human anti-CD4bs nmAb neutralized SHIV-1157ipEL-p
Table 2. Sensitivity of R5 SHIV strains to soluble CD4, human nmAbs and serum samples.
IC50 (mg/ml) in TZM-bl cells
a IC50 (reciprocal serum dilution) in TZM-bl cells
a
SHIV strain sCD4 IgG1 12 2G12 2F5 4E10 HIVIG BB47 BB55 BB68 BB75 BB80 BB81 BB87 Tier
Clade C
SHIV-1157ipEL (early/late
chimera mol. clone)
1.7 0.7 .25 .25 .25 88.6 4,274 3,286 666 1,245 1,822 691 3,278 1
SHIV-1157ipEL-p (early/late
chimera; RM passaged)
0.5 1.4 .25 .25 .25 150.8 1,193 1,792 653 824 1,135 427 2,707 1
SHIV-1157ipd3N4
b
(late isolate)
0.4 7.0 .25 .25 .25 1,160 105 131 86 79 72 47 260 2
SHIV-2873Nip
b
(early isolate)
1.5 .25 .25 .25 .25 .2,500 ,20 70 266 66 56 ,20 25 2
Clade B
SHIVSF162P4
b 0.2 ,0.01 15.7 1.5 0.7 25 363 2,543 328 615 828 211 3,603 1
SHIVSF162P3
b 11.6 6.0 .25 .25 .2 5 1 , 5 0 5 2 46 52 22 72 5,20 180 2
Spectrum of neutralization sensitivity of R5 SHIV strains encoding HIV clade B or C env. SHIV-C strains were grown in human PBMC.
avalues represent the concentration (mg/ml for soluble CD4 (sCD4) and human nmAbs IgG1b12, 2G12, 2F5, 4E10, or HIVIG) or the dilution (for serum samples) at which
relative luciferase units (RLU) were reduced 50% compared to virus control wells. BB47, BB55, BB68, BB75, BB80, BB81, and BB87 are serum samples from individuals
infected with HIV-1 clade C. HIVIG, polyclonal high-titer anti-HIV Ig preparation.
bdata previously published [11] and given as basis of comparison.
doi:10.1371/journal.pone.0011689.t002
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PLoS ONE | www.plosone.org 6 July 2010 | Volume 5 | Issue 7 | e11689Figure 5. (A) Sequence alignment of V1/V2 sites of and SHIV-1157ipEL-p, SHIV-1157ipEL-pD3N and SHIV-1157ipd3N4 (numbering according to
HXB2). (B) Molecular modeling of SHIV-1157ipEL-p and SHIV-1157ipd3N4 sequences was performed using the X-ray structure of the CD4-bound YU2
gp120 core [20]; PDB code 1RZK). The V1, V2, and V3 loops were modeled onto the core. Mutations inducing structural heterogeneity in the V1 and
V2 loops were identified. (C and D) Illustration of three-dimensional (3D) gp120 of SHIV-1157ipEL-p (white), SHIV-1157ipd3N4 (green), and (D) SHIV-
1157ipEL-pD3N (yellow) showing that access to the CD4 binding site (red) is more restricted for SHIV-1157ipEL-pD3N and SHIV-1157ipd3N4 than for
SHIV-1157ipEL-p.
doi:10.1371/journal.pone.0011689.g005
Table 3. Neutralization titers of autologous and heterologous polyclonal serum/plasma samples against SHIV-1157ipEL-p (early
Env) and SHIV-1157ipd3N4 (late Env).
Plasma
R5 SHIV strain harbored by rhesus
monkeys (RM) and animal name Titers (serum/plasma dilution at 50% neutralization)
SHIV-1157ipEL-p SHIV-1157ipd3N4
Autologous SHIV-1157ip-infected RM (early virus)
RIj-11 88 ,10
REk-11 .640 ,10
RAo-8 560 32
RKl-8 148 47
RTs-7 93 20
SHIV-1157ipd3N4-infected RM (late virus)
RQ3911 140 30
RJs-10 110 23
Rho-10 336 84
RBg-9 40 36
Heterologous SHIV-2873Nip-infected RM
RBg-10 90 18
RUf-10 54 ,10
RNt-9 340 ,10
RTb-11 28 ,10
Autologous plasma samples were collected from 6 months to 3 years post-inoculation; heterologous plasma samples were collected from 6 months to 1 year
post-inoculation. SHIV-C strains were grown in RM PBMC.
doi:10.1371/journal.pone.0011689.t003
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1157ipd3N4 were not neutralized even at the highest nmAb
concentration tested (40 mg/ml; Fig. 6B). These findings imply
that V2 loop orientation may be sufficient to change the
neutralization profile by regulating the access to the CD4bs.
Mucosal transmissibility of SHIV-1157ipEL-p
Since mucosal transmission is a major mode for HIV
acquisition in humans, candidate AIDS vaccines should be
designed to protect against mucosal virus exposures. Thus,
primate challenge models should test vaccine safety and efficacy
also in relation to this route (reviewed in [21]). We generated a
large stock of SHIV-1157ipEL-p in RM PBMC and determined
its ability to cause systemic infection after repeated weekly, low-
dose intra-rectal (i.r.) challenges using a maximum of five weekly
inoculations. Of the two RM exposed to a weekly dose of 5,000
TCID50, one animal became viremic after three inoculations,
while the second RM remained aviremic and was subsequently
given a single dose of 1.5610
5 TCID50 that promptly resulted in
high viremia (Fig. 7). Another two RM were challenged weekly
with 8,000 TCID50; all became viremic after 3 or 4 inoculations.
Lastly, two RM given 10,000 TCID50 became systemically
infected after 2 or 3 weekly inoculations (Fig. 7). In the interim,
SHIV-1157ipEL-p has been used in vaccine challenge studies
using a maximum of five weekly inoculations with 8,000 TCID50
Overall, a total of 17 unvaccinated RM have been challenged
with this regimen; 16 have developed systemic infection (94%),
Figure 6. Neutralization of SHIV-1157ipEL-p, SHIV-1157ipEL-pD3N and SHIV-1157ipd3N4 by sCD4 and b12. The assays were
performed in TZM-bl cells using virus stocks grown in RM PBMC. (A) Dotted lines, neutralization of SHIV-1157ipEL-p (circles), SHIV-1157ipEL-pD3N (red
color with triangles) and SHIV-1157ipd3N4 (squares) using sCD4; solid lines, neutralization of the above SHIVs using the human nmAb b12. (B) Values
represent the concentration (mg/ml) for sCD4 and human b12 at which relative luciferase units (RLU) were reduced 50% or 90% compared to virus
control wells, respectively.
doi:10.1371/journal.pone.0011689.g006
Figure 7. Intrarectal inoculation of SHIV-1157ipEL-p. Six
monkeys were used in a repeated low-dose i.r. titration; the aim was
to find a virus dose that resulted in systemic infection (defined as viral
RNA $10
4 copies/ml) after a maximum of five weekly i.r. inoculations.
RM remaining uninfected at week 2 after the 5
th weekly low-dose virus
challenge were given a single high-dose of SHIV-1157ipEL-p (1.5610
5
TCID50). The green half-diamonds represent mean 6 SD of 15 additional
RM used in unpublished vaccine efficacy studies as unvaccinated
controls; these animals were given maximally five weekly i.r.
inoculations at 8,000 TCID50. The horizontal dotted line indicates lower
limit of detection (,50 viral RNA copies/ml).
doi:10.1371/journal.pone.0011689.g007
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repeated low-dose titration.
Signs of SHIV-1157ipEL-p pathogenicity
Within 3–6 months of follow-up, all the SHIV-1157ipEL-p-
infected monkeys have maintained absolute CD4 T-cell counts in
peripheral blood of .500 cells/ml. However, from approximately
8 weeks post-inoculation onwards, peripheral blood CD4
+
memory T cells (assessed by CD4
+CD29
+ double staining) have
been persistently low (,10%) in all infected animals (data not
shown). Depletion of CD4
+CD29
+ cells has been predictive of
depletion of absolute CD4
+ T-cell counts [10,22]. Previous reports
have shown that depletion of gut CD4
+ T cells in acute infection is
typical hallmark of HIV infection (reviewed in [23]). We therefore
assessed the effect of SHIV-1157ipEL-p on rectal and lymph node
lymphocytes during acute-stage infection (2–12 weeks post-
inoculation). Compared to uninfected controls, the percentage of
CD4
+ T cells among the lymphocytes isolated from blood, lymph
nodes, and gut in all the infected monkeys tested was significantly
lower (p,0.05; Mann-Whitney test; Fig. 8).
Discussion
We describe the development and characterization of the R5
SHIV-1157ipEL-p that encodes an early env from an African
pediatric HIV-C isolate. We compared structural and neutraliza-
tion profiles of the new SHIV-1157ipEL-p with that of a SHIV
that encodes the late version of the same envelope, SHIV-
1157ipd3N4. A number of distinctive features can be ascribed to
SHIV-1157ipEL-p: 1) it carries env of an early, relatively recently
transmitted HIV-C; 2) SHIV-1157ipEL-p contains additional NF-
kB sites in the LTRs; 3) it contains the backbone of the late SHIV-
1157ipd3N4, which also has a deletion in the 39 end of HIV env
that restored the original SIVmac239 env C-terminus allowing it to
extend into the original SIV nef overlap region [1]; 4) SHIV-
1157ipEL-p is exclusively R5 tropic; 5) it is highly sensitive to
neutralization with a tier 1 profile; 6) it is mucosally transmissible
and can be used to assess candidate AIDS vaccine efficacy against
mucosal exposure; 7) signs of SHIV-1157ipEL-p pathogenicity in
RM include memory T-cell depletion in blood, and loss of CD4
+
T cells in PBMC, lymph node and gut during acute viremia; and
8) the HIV-C Env evolution in our SHIV-C-infected RM
recapitulated patterns of molecular evolution observed in HIV-
infected humans, including individuals harboring HIV-C [24,25].
Genetic analysis of SHIV-1157ipEL-p env showed just three
point mutations throughout the envelope when compared to the
parental chimera SHIV-1157ipEL, indicating that our rapid,
every two-week passage strategy resulted in only minor Env
changes. Consistent with this finding is the maintenance of the tier
1 neutralization profile. In contrast, our tier 2 SHIV strains,
SHIV-1157ipd3N4 and SHIV-2873Nip, showed extensive muta-
tions and amino acid deletions throughout the gp160 when
reisolated 2.7 and 1 years post-inoculation, respectively, when
compared to the parental infectious molecular clones [25]. These
more extensive mutations seen after long-term in vivo replication
were associated with a change to a tier 2 profile for SHIV-
1157ipd3N4.
SHIV-1157ipd3N4 and SHIV-1157ipEL-p are 90% identical in
their Env amino acid sequences but differ markedly in their
neutralization profiles. Previous reports demonstrated that modifica-
tions of N-glycosylation sites, variable loop lengths, charges of amino
acid residues or a combination of these factors are responsible for
differences in neutralization profiles [7,19,24,25,26,27,28,29,30,31,
32,33,34,35,36], including data from clade B SHIV/macaque
models [37,38,39,40,41,42,43]. We did not find any significant
differences in the early and late SHIV-C Env sequences, with the
exception of the loss of one PNG site in the V2 loop in SHIV-
1157ipd3N4. Several studies have indicated that the majority of
changes in charged amino acids occur in the V1/V2 loops of gp120
and affect neutralization sensitivity [42,44,45,46,47,48,49,50]. In our
study, differences in neutralization sensitivity were linked to the V1,
V2 and V3 loops of viruses encoding ‘‘early’’ forms of the 1157ip
envelopes containing disproportionately more basic amino acids
compared to the ‘‘late’’ Env of SHIV-1147ipd3N4. Recently, Wu et
al. [19] showed that increasing the number of positively charged
amino acids in gp120 enhanced exposure of the CD4bs, which
rendered virus more sensitive to nAbs. Together, these findings
indicate that changes in charge could be an important determinant of
neutralization sensitivity.
Interestingly, the ‘‘early’’ SHIV-1157ipEL-p Env has a longer
V2 loop than the ‘‘late’’ SHIV-1157ipd3N4. This is in contrast to
the observations of Li et al. [7], who reported that recently
transmitted HIV-C strains had shorter variable loop regions
compared to all HIV-C strains in the database. Others have
postulated that variable loop length is an important determinant
for neutralization sensitivity, and V1/V2 loops have been
proposed to act as protective barriers around the CD4bs, masking
its accessibility to nAbs, thus resulting in different neutralization
profiles [47,48,50,51,52]. In our comparison of ‘‘early’’ and ‘‘late’’
forms of the HIV-C Env molecules in the 1157i series, we found
that the V2 loop is packed closer to the CD4bs in the case of the
‘‘late’’ SHIV-1157ipd3N4, which probably restricted nAb access
to the CD4bs, as reflected in the IC50 and IC90 values for nmAb
b12. Changes in the positions of the variable loops have been
linked to increasing neutralization resistance by Ye et al. [43], who
analyzed Env mutations that arose when the clade B SHIV-
HXBc2, which encodes a laboratory-adapted, neutralization-
sensitive HIV env, was passaged in macaques to yield the highly
pathogenic SHIVKU-1. The env gene of the latter was swapped
with the ‘‘early’’ env gene in SHIV-HXBc2, giving rise to SHIV-
HXBc2P 3.2, which not only caused rapid CD4+ T-cell depletion
but was also significantly more neutralization resistant than the
‘‘early’’ SHIV-HXBc2. Antibody competition analysis, used to
Figure 8. T-cell depletion during acute SHIV-1157ipEL-p
viremia. The percent CD4
+ T cells in blood, lymph node and gut was
estimated compared with cells from naı ¨ve monkeys (closed symbols).
Biopsy specimens were collected during the acute phase of infection.
Two of the 2-week time points were obtained from last two i.v.-
inoculated RM used for viral adaptation, the remainder were collected
from RM undergoing the 5x weekly i.r. challenge-dose titration. We
assigned peak viremia as being week 2 after the pen-ultimate i.r.
inoculation, the one that most likely was successful in achieving
systemic infection. Individual time points are shown with different
symbols (open squares, week 2; open triangles, week 5; open circles,
week 12).
doi:10.1371/journal.pone.0011689.g008
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implied a close proximity of the V2 and V3 loops to the gp120
core and the CD4bs, thus restricting access of nAbs and soluble
CD4 to the CD4bs. Of note, the molecular modeling we employed
here to analyze HIV-C Env mutations arising during the course of
SHIV-C infection arrived at same conclusion that increasing
neutralization resistance is linked to the position of V2 with
regards to the CD4bs. In fact, molecular modeling predicted that
the short NNN deletion in V2 of the tier 1 virus, SHIV-1157ipEL-
p, might be sufficient to hinder access to the CD4bs. This
prediction was confirmed experimentally with an isogenic virus
that differed only in the NNN residues at positions 185–187 from
the ‘‘early’’ virus: sensitivity of the two viruses to b12 was very
different as only SHIV-1157ipEL-p was susceptible to this nmAb.
Therefore, our current results on SHIV-C constructs in RM
emphasize the importance of V2 loop position relative to the
CD4bs in determining neutralization sensitivity.
Two recent studies showed that different pathways were
involved in the neutralization escape of early forms of HIV-C
from autologous antibodies in South African individuals [24,25].
As expected, later viruses were more difficult to neutralize by
contemporaneous autologous sera. In one study, HIV-C
neutralization escape was driven by modifications in V1/V2 or
the alpha-2 helix of C3 [24], whereas Rong et al. [25] noted that
changes in V1 to V5 with involvement of V1 and gp41 regions
predominated during HIV-C Env evolution in their study
subjects. In our case, a few changes in V2 between SHIV-
1157ipEL-p and SHIV-1157ipd3N4 could explain the difference
in neutralization profiles, which is one of the sites associated with
HIV-C neutralization escape in infected humans. Interestingly,
monkeys challenged with ‘‘late’’ SHIV-1157ipd3N4 had much
higher neutralization titers against the early form, SHIV-
1157ipEL-p, than the autologous late SHIV-1157ipd3N4. Taken
together, our SHIV-C data suggest that HIV-C envelope
evolution that occurred under the selective pressure of RM nAbs
displays some of the hallmarks of HIV-C Env evolution in seen in
chronically infected humans.
SHIV-1157ipEL-p infection resulted in high peak viral RNA
loads and signs of pathogenicity during acute infection. Studies
with SIV-infected RM and HIV-infected humans document that
acute infection is accompanied by a marked depletion of CD4
+
memory T cells primarily in mucosal tissues [53,54,55]. We
observed loss of memory CD4
+CD29
+ T cells in peripheral blood
and a depletion of CD4
+ T cells in the blood, lymph nodes and
gut tissues of SHIV-1157ipEL-p-infected RM. This pattern
resembles the one reported in acutely HIV-infected humans
[53,54,55]. Together, our in vivo data indicate that SHIV-
1157ipEL-p is highly replication-competent and exhibits early
signs of pathogenicity. Prolonged prospective follow-up will reveal
the full spectrum of disease associated with this R5 SHIV-C
strain. Of note, both SHIV-1157ip, the donor of the env gene, and
SHIV-1157ipd3N4, the donor of the backbone, are pathogenic
and have induced AIDS within 3 years [10,16]. We expect that
SHIV-1157ipEL-p-infected RM will progress to AIDS, since we
used the late backbone and the early-passage env to build this
chimera.
SHIV-1157ipEL-p was classified as a tier 1 virus based on its
high susceptibility to neutralization. This property allows for its use
as a challenge virus for nAb-response-based AIDS vaccine trials in
RM. In fact, it is the only R5 SHIV-C tier 1 virus described to
date. Although we have previously reported the construction and
biological properties of two R5 SHIV-C strains, SHIV-
1157ipd3N4 and SHIV-2873Nip, both were determined to be
tier 2 viruses with neutralization sensitivity profiles typically seen in
primary HIV isolates. In addition to our matched tier 1/tier 2 R5
SHIV-Cs based upon envelopes from HIV1157i, another tier 1/
tier 2 pair of R5 SHIVs has been described, which are based upon
the R5 envelopes of HIVSF162, a clade B strain. The parental
SHIVSF162 gave rise to SHIVSF162P3/SHIVSF162P4 during sequen-
tial blood/bone marrow transfers from an infected RM donor to
new recipients [56,57,58]; SHIVSF162P3 and SHIVSF162P4 differ in
their neutralization sensitivities and are classified as tier 2 and tier
1 strains, respectively. Interestingly, the tier 1 strain arose in an
animal from a later passage compared to the tier 2 SHIVSF162P3
[56]. In contrast, the envelope in our ‘‘late’’ SHIV-1157ipd3N4
represents a neutralization escape variant of the early Env version.
Since induction of high nAb levels with extended breadth is a
major hurdle in developing an effective AIDS vaccine and current
immunogens have generally not induced nAbs capable of
neutralizing heterologous tier 2 viruses in vitro, it is informative
to evaluate candidate anti-HIV-C AIDS vaccines by testing
efficacy with a tier 1 R5 SHIV-C challenge virus in primate
models when tier 2 challenge viruses are not neutralized in vitro.
Once substantial protection is achieved against a tier 1 challenge
virus, the subsequent steps in vaccine development would involve
immunogen optimization and then employ tier 2 R5 SHIV
challenge strains, such as SHIV-1157ipd3N4 or SHIV-2873Nip
[11]. Of note though, our results revealed an intriguing finding:
monkeys infected with the late, tier 2 SHIV-1157ipd3N4 showed
equal or better neutralization titers for the tier 1 isolate SHIV-
1157ipEL-p, even though these animals were never exposed to the
early version of this HIV-C Env. This finding may need to be
taken into account for the design of effective immunogens against
tier 1 and tier 2 isolates.
In summary, with the use of our R5 SHIV-C constructs in RM,
SHIV-1157ipEL-p, SHIV-1157ipd3N4 and related viruses, we
have shown that natural evolution of Env sequences was
predominantly associated with changes in the V2 loops, which
influenced neutralization sensitivity profiles. As such, the molec-
ular evolution of HIV-C Env in the context of a pathogenic R5
SHIV in rhesus monkeys recapitulated HIV-C Env evolution in
humans. SHIV-1157ipEL-p and its tier 2 counterpart, SHIV-
1157ipd3N4, will be biologically relevant tools to evaluate vaccine
candidates designed to induce anti-HIV-C nAb responses in
primate model studies.
Materials and Methods
Original virus isolates and nomenclature
SHIV-1157i represents the initial infectious molecular clone
that encodes env of a primary HIV-C, HIV1157i, isolated from the
relatively recently infected Zambian infant 1157i [1,10]; ‘‘i’’
indicates a virus strain (or env gene) isolated from a human infant.
SHIV-1157ip is the initial RM-adapted biological isolate (‘‘p’’
designates a passaged, i.e., monkey-adapted form) [10] that was
pathogenic but caused disease slowly [10] (Table 1). To generate a
more replication-fit virus, an infectious molecular clone was
generated by directly cloning a virus from a SHIV-1157i-infected
RM after it had developed AIDS 2.7 years post-inoculation. The
resulting SHIV-1157ipd3N4 clone was also engineered to contain
two NF-kB sites per LTR, instead of the usual single NF-kB site
that is present in the LTR of SIVmac239, the backbone used to
generate the SHIV constructs. The late-stage SHIV-1157ipd3N4,
however, was relatively difficult to neutralize. SHIV-1157ipEL, an
infectious molecular clone, represents a chimera generated by
inserting an early form of the SHIV-1157ip env into the backbone
of the late SHIV-1157ipd3N4. SHIV-1157ipEL-p is a biological
isolate obtained after a short, serial passage of SHIV-1157ipEL
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weeks post-inoculation (Table 1).
Construction of SHIV-1157ipEL molecular clones
SHIV-1157ip, an early biological isolate, was PCR-amplified
using high-fidelity DNA polymerase and the following primer
pairs:59GGGGGAAGCTTATGAGAGTGATGGGGATACAG-
AGG-39 and 59-CCCCCTCGAGTTATTGCAAAGCTGCTT-
CAAAGCCC-39. The full-length SHIV-1157ip env was digested
with restriction enzymes HindIII and XhoI and cloned into the
vector pcDNA6/myc-His B (Invitrogen, Carlsbad, CA). After
digestion with KpnI (K)-BamHI (B), a 2.2 kb fragment of SHIV-
1157ip env (spanning most of gp120, the entire gp41 extracellular
domain, the transmembrane region (TM), and part of the
cytoplasmic domain) was obtained and used to replace the
corresponding region of SHIV-1157ipd3N4 env. The modified
39-half was ligated with the 59-half of SHIV-1157ipd3N4 [1]
proviral DNA to generate full-length SHIV-1157ipEL.
Co-receptor usage of SHIV constructs
The U87 or GHOST cell lines expressing CD4 alone or CD4
and HIV-1/SIV co-receptors, obtained from the NIH AIDS
Research & Reference Reagents Program (ARRRP, Germantown,
MD),wereusedtostudyviraltropism.U87.CD4,U87.CD4.CCR1,
U87.CD4.CCR2, U87.CD4.CCR3, U87.CD4.CXCR4, U87.
CD4.CCR5, GHOST.BOB, and GHOST.BONZO were infected
with stocks of SHIV-1157ipEL and SHIV-1157ipEL-p. SHIV-
1157ipd3N4 (clade C, R5) and NL4-3 (clade B, X4) were used as
controls. Cells were washed and resuspended in 1 ml of fresh
medium. Supernatants were collected on days 0, 1, 3, and 5, for
estimation of p27.
Replication kinetics in rhesus macaque PBMC
PBMC from randomly selected naı ¨ve RM donors were
stimulated with concanavalin A (Con-A) (5 mg/ml), followed by
the addition of interleukin-2 (IL-2) (20 U/ml) for 72h. PBMC were
washed twice and exposed to supernatant containing SHIV-
1157ipEL or SHIV-1157ipEL-p viruses and incubated for 2 h at
37uC. PBMC were washed twice and added to wells at 2610
6/
well in 12-well plates. Starting from day of exposure, 200 ml of the
medium were harvested and replaced every second day with fresh
medium (containing IL-2) up to day 20 and assayed for p27 levels.
Animals and animal care
RM (Macaca mulatta) of Indian origin were housed at the Yerkes
National Primate Research Center (YNPRC, Emory University,
Atlanta, GA) according to U.S. Public Health Service/National
Institutes of Health guidelines on the care and use of laboratory
animals that include recommendations for animal welfare and
procedures to ameliorate suffering of non-human primates.
YNPRC facilities are fully accredited by the Association for
Assessment and Accreditation of Laboratory Animal Care
International. Animal experiments were approved by the Institu-
tional Animal Care and Use Committees of 1) YNPRC on 11/21/
2008 and continuing approval on 11/21/2009 (protocol # 261-
2008Y), and 2) the Dana-Farber Cancer Institute via a
Collaborating Institution Animal Use Agreement.
Serial passage of SHIV-1157ipEL
RM REk-11 was inoculated i.v. with 10 ml of a SHIV-
1157ipEL stock prepared from RM PBMC. After REk-11 was
confirmed to be virus-positive as assessed by real-time RT-PCR
[59] at week 1 post-inoculation, 10 ml of blood from this RM was
transferred i.v. to monkey RIj-11. Serial blood transfer was
performed at 2 weeks post-inoculation, during the expected time of
peak viremia (Fig. 4A). All animals were monitored for viral loads,
antibody responses, and T-cell subsets.
Measurement of plasma viral RNA levels
Plasma viral RNA was isolated by use of the QiaAmp Viral
RNA Mini-Kit (Qiagen) and viral RNA levels were measured by
quantitative reverse-transcriptase polymerase chain reaction (RT-
PCR) for SIV gag sequences [59] on weeks 0, 1, 2, 4, 8, and at
monthly intervals thereafter. Assay sensitivity was determined to
be 50 viral RNA copies/ml. Additionally, primers/probes and
conditions according to Lifson were used [60].
PCR and sequencing analysis
Chromosomal DNA from 10
6 PBMC was extracted from
animal ROm-8 at peak viremia (2 weeks after receiving infected
blood from the penultimate RM) using a DNAzol genomic DNA
isolation kit (Molecular Research Center Inc., Cincinnati, OH).
To analyze the molecular evolution of SHIV-1157ipEL-p env
during in vivo passaging, two different primers were synthesized to
amplify the env gene (approximately 2.2 kb) of SHIV-1157ipEL-p
that was isolated from monkey ROm-8 at 2 weeks post-
inoculation. The following pair of primers was used: forward (59
-AGTCTATTATGGGGTACCTGTATGGAAAGAAGCA-39)
and reverse (59-TCCCAGATAAGTGCCAAGGATCCGTT-
CACTAATC -39); PCR was carried out under end-point dilution
conditions. The amplified fragment was cloned into the KpnI and
BamHI sites of a pcDNA6/myc-His B vector for sequencing. DNA
sequencing was performed for five randomly selected clones
encoding an env gene.
Generation of a large-scale SHIV-1157ipEL-p stock
A large-scale stock of the uncloned biological virus isolate was
prepared by cocultivation of SHIV-1157ipEL-p-infected PBMC
derived from monkey ROm-8 two weeks post-inoculation (the
time of peak viremia) with naı ¨ve RM PBMC. The latter had been
stimulated with concanavalin A and were cultured in the presence
of human interleukin-2 (IL-2) (20 U/ml) and TNF-a (10 ng/ml).
The resulting stock has a p27 concentration of 50 ng/ml and
1.5610
5 50% tissue culture infectious doses (TCID50) per ml, as
titrated in TZM-bl cells [14].
Neutralization assays
The neutralization sensitivity of SHIV-1157ipEL-p was deter-
mined using the TZM-bl reporter cell line-based neutralization
assays as described previously [7,15]. TZM-bl cells (also called
JC53-bl [14] cells (ARRRP) stably express CD4 and CCR5 as well
as luciferase and b-galactosidase under the control of the HIV-1
LTR. In brief, virus was added to cells in the presence of DEAE
dextran (40 mg/ml), washed 1x on day 1 and measured in a
luminometer (Perkin Elmer, Waltham, MA) on day 2 after adding
luciferase substrate (Bright-Glo, Promega, Madison, WI).
Serial dilutions of either RM sera or mAbs were prepared in
triplicate in 96-well plates; virus was added (50–200 TCID50) and
incubated for 1 h at 37uC before adding to the TZM-bl plates. For
assays that employed immune sera, neutralization titers were
calculated based on virus production in wells containing sera
pooled from four naive RM as negative controls. The concentra-
tion of serum giving 50% neutralization of virus production (IC50)
was calculated using the level of virus production in control wells
that contained the same dilution of pooled naive sera. For mAb
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and cells only (i.e., no serum).
Sequence and structural analysis
N-linked glycosylation sites were tracked using the LANL N-
Glycosite program (http://www.hiv.lanl.gov/content/sequence/
GLYCOSITE/glycosite.html). Potential N-linked glycosylation
(PNG) sites were mapped on a model structure of gp120. Protein
modeling and energy calculations were performed using Discovery
Studio (Accelrys Software, Inc.) based on a sequence alignment
with the core structure corresponding to the X-ray structure of
YU2 [20] (pdb code 1RZK). V1, V2, and V3 loops were added to
the core structure as previously described [37] and refined by the
loop refinement program. Energies were calculated using
CHARMM (Chemistry at Harvard Macromolecular Mechanics).
We introduced solvent factors using the implicit of distance-
dependent dielectrics model and performed energy minimization
of Env loops (Steepest Descent following by Conjugate Gradient).
Nucleotide sequence accession number
The complete nucleotide sequence of the env gene of SHIV-
1157ipEL-p has been submitted to Genbank; an accession number
is HM585377.
Site-directed mutagenesis to create the mutant
SHIV-1157ipEL-pD3N
To create the NNN deletion mutant, SHIV-1157ipEL-pD3N,
from SHIV-1157ipEL-p, two different sets of primers were
synthesized. Forward (59 -TCTATTATGGGGTACCTGTATG-
GAAAGAAG-39); reverse (59-TAACACCACTTGATGAGAA-
TTCTAGTGAGTATAGATTAAT-39) and forward (59-AT-
TAATCTATACTCACTAGAATTCTCATCAAGTGGTGTT-
A-39); reverse (59-TAAGTGCCAAGGATCCGTTCACTAATC-
GAA-39). The full-length SHIV-1157ipEL-p env, cloned into the
vector pcDNA6/myc-His B (Invitrogen, Carlsbad, CA), was used
as template to create mutant SHIV-1157ipEL-pD3N env using
overlapping PCR. The amplified fragment was cloned into the
KpnI (K) and BamHI (B) sites of a pcDNA6/myc-His B vector and
confirmed by sequencing. An infectious molecular clone of SHIV-
1157ipEL-pD3N was generated using a similar strategy as that
described above for SHIV-1157ipEL.
Intrarectal inoculation of SHIV-1157ipEL-p and isolation
of mucosal lymphocytes
Six animals received repeated weekly low-dose intrarectal (i.r.)
inoculations (up to a maximum of 5): 5,000 TCID50 (two RM),
8,000 TCID50 (two RM) and 10,000 TCID50 (two RM). Monkeys
that remained either aviremic or had only transient, low-level
viremia (,10
4 copies/ml) at the 2-week time point after the 5
th
low-dose virus exposure were given a single high-dose i.r.
challenge (1.5610
5 TCID50). Blood was collected at 0, 1, 2, 4,
8, and 12 weeks post-inoculation to determine viral RNA loads
and T-cell subsets. PBMC were isolated by standard procedures;
lymphocytes from rectal biopsies were obtained by digestion with
collagenase followed by a separation step using Percoll gradients as
described previously [11]. For subset analyses of T cells,
approximately 1610
6 PBMC or lymphocytes from rectal biopsies
were surface-stained as described [11].
Statistical analysis
PrismH (GraphPad Software, version 4, CA) was used to
compare percentages and numbers of lymphocytes between
groups of uninfected and SHIV-1157ipEL-p-infected animals
using the Mann-Whitney test.
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